Binding of HIV-1 virions to α4β7 expressing cells and impact of antagonizing α4β7 on HIV-1 infection of primary CD4+ T cells

Virologica Sinica

Volumn 29, Issue 6, 2014, Pages 381-392

  Li, Chang ^a,b   Jin, Wei ^a,b   Du, Tao ^a   Wu, Biao ^c   Liu, Yalan ^a   Shattock, Robin J ^d   Hu, Qinxue ^a,e  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c WUHAN NO 1 HOSPITAL   (China)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

binding; HIV 1; infection; integrin 4 7; primary CD4+ T cells; RNA interference

Indexed keywords

ALPHA4BETA7 INTEGRIN; ALPHA4BETA7 INTEGRIN ANTIBODY; GLYCOPROTEIN GP 120; INTEGRIN; LENTIVIRUS VECTOR; PROTEIN ANTIBODY; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; INTEGRIN ALPHA4BETA7; PROTEIN BINDING; VIRUS RECEPTOR;

ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN BA L); HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOCYTE HOMING; MOUSE; NONHUMAN; PRIMARY CELL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; RNA INTERFERENCE; STABLE EXPRESSION; STABLE TRANSFECTION; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS ATTACHMENT; VIRUS ENVELOPE; VIRUS STRAIN; CELL CULTURE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; PHYSIOLOGY; VIROLOGY;

CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HIV INFECTIONS; HIV-1; HUMANS; INTEGRINS; PROTEIN BINDING; RECEPTORS, VIRUS; VIRION; VIRUS ATTACHMENT;

EID: 84925544956     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-014-3525-8     Document Type: Article

References (55)

1. Abram C L, Lowell C A. 2009. The ins and outs of leukocyte integrin signaling. Annu Rev Immunol, 27: 339–362.
2. Alvarez R A, Thorborn G, Reading J L, Reddy S K, Vyakarnam A. 2011. WFDC1 expression identifies memory CD4 T-lymphocytes rendered vulnerable to cell-cell HIV-1 transfer by promoting intercellular adhesive junctions. Retrovirology, 8: 29.
3. 7-mediated adhesion to vascular cell adhesion molecule-1, mucosal addressin-1, fibronectin, and lymphocyte aggregation. J Immunol, 153: 3847–3861.
4. 7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol, 9: 301–309.
5. 7 integrin mediates lymphocyte binding to the muco sal vascular addressin MAdCAM-1. Cell, 74: 185–195.
6. Birmingham A, Anderson E, Sullivan K, Reynolds A, Boese Q, Leake D, Karpilow J, Khvorova A. 2007. A protocol for designing siRNAs with high functionality and specificity. Nat Protoc, 2: 2068–2078.
7. Boily M C, Baggaley R F, Wang L, Masse B, White R G, Hayes R J, Alary M. 2009. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis, 9: 118–129.
8. Borrow P, Shattock R J, Vyakarnam A. 2010. Innate immunity against HIV: a priority target for HIV prevention research. Retrovirology, 7: 84.
9. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, Overbaugh J. 2005. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1–V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol, 79: 6528–6531.
10. Cicala C, Arthos J, Fauci A S. 2010. HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV. J Transl Med, 9Suppl 1: S2.
11. 7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci USA, 106: 20877–20882.
12. Dale B M, Alvarez R A, Chen B K. 2013. Mechanisms of enhanced HIV spread through T-cell virological synapses. Immunol Rev, 251: 113–124.
13. 7. PLoS One, 6: e24461.
14. Derdeyn C A, Decker J M, Bibollet-Ruche F, Mokili J L, Muldoon M, Denham S A, Heil M L, Kasolo F, Musonda R, Hahn B H, Shaw G M, Korber B T, Allen S, Hunter E. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science, 303: 2019–2022.
15. Etemad B, Redd A, Serwadda D, Lutalo T, Reynolds S, Gray R, Quinn T, Sagar M. 2012. Envelopes found early after acquisition compared to those in the chronically infected partner do not have enhanced alpha4 beta7 binding or utilization. Retrovirology, 9: P149.
16. Haase A T. 2010. Targeting early infection to prevent HIV-1 mucosal transmission. Nature, 464: 217–223.
17. Harris A, Borgnia M J, Shi D, Bartesaghi A, He H, Pejchal R, Kang Y K, Depetris R, Marozsan A J, Sanders R W, Klasse P J, Milne J L, Wilson I A, Olson W C, Moore J P, Subramaniam S. 2011. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci U S A, 108: 11440–11445.
18. Hu Q, Napier K B, Trent J O, Wang Z, Taylor S, Griffin G E, Peiper S C, Shattock R J. 2005. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization. J Mol Biol, 350: 699–712.
19. Jelicic K, Cimbro R, Nawaz F, Huang da W, Zheng X, Yang J, Lempicki R A, Pascuccio M, Van Ryk D, Schwing C, Hiatt J, Okwara N, Wei D, Roby G, David A, Hwang I Y, Kehrl J H, Arthos J, Cicala C, Fauci A S. 2013. The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-beta1 production and FcRL4 expression. Nat Immunol, 14: 1256–1265.
20. Keele B F, Giorgi E E, Salazar-Gonzalez J F, Decker J M, Pham K T, Salazar M G, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr J L, Gao F, Anderson J A, Ping L H, Swanstrom R, Tomaras G D, Blattner W A, Goepfert P A, Kilby J M, Saag M S, Delwart E L, Busch M P, Cohen M S, Montefiori D C, Haynes B F, Gaschen B, Athreya G S, Lee H Y, Wood N, Seoighe C, Perelson A S, Bhattacharya T, Korber B T, Hahn B H, Shaw G M. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA, 105: 7552–7557.
21. Kishko M, Somasundaran M, Brewster F, Sullivan J L, Clapham P R, Luzuriaga K. 2011. Genotypic and functional properties of early infant HIV-1 envelopes. Retrovirology, 8: 67.
22. 7-dependent killing of CD4-negative γδ T cells which are lost during progression to AIDS. Blood, 118: 5824–5831.
23. Liao Z, Roos J W, Hildreth J E. 2000. Increased infectivity of HIV type 1 particles bound to cell surface and solid-phase ICAM-1 and VCAM-1 through acquired adhesion molecules LFA-1 and VLA-4. AIDS Res Hum Retroviruses, 16: 355–366.
24. Liu J, Bartesaghi A, Borgnia M J, Sapiro G, Subramaniam S. 2008. Molecular architecture of native HIV-1 gp120 trimers. Nature, 455: 109–113.
25. Luo B H, Carman C V, Springer T A. 2007. Structural basis of integrin regulation and signaling. Annu Rev Immunol, 25: 619–647.
26. 4+ T cells correlates with susceptibility to rectal SIV infection. J Acquir Immune Defic Syndr, 64: 325–331.
27. 4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest, 122: 62–69.
28. 4+ T cell subset coexpressing multiple markers of HIV susceptibility. J Immunol, 187: 6032–6042.
29. McLellan J S, Pancera M, Carrico C, Gorman J, Julien J P, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O’Dell S, Patel N, Shahzad-ul-Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington J C, Chuang G Y, Diwanji D, Georgiev I, Kwon Y D, Lee D, Louder M K, Moquin S, Schmidt S D, Yang Z Y, Bonsignori M, Crump J A, Kapiga S H, Sam N E, Haynes B F, Burton D R, Koff W C, Walker L M, Phogat S, Wyatt R, Orwenyo J, Wang L X, Arthos J, Bewley C A, Mascola J R, Nabel G J, Schief W R, Ward A B, Wilson I A, Kwong P D. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature, 480: 336–343.
30. 4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med, 200: 761–770.
31. Miller C J, Li Q, Abel K, Kim E Y, Ma Z M, Wietgrefe S, La Franco-Scheuch L, Compton L, Duan L, Shore M D, Zupancic M, Busch M, Carlis J, Wolinsky S, Haase A T. 2005. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol, 79: 9217–9227.
32. Mora J R, Bono M R, Manjunath N, Weninger W, Cavanagh L L, Rosemblatt M, Von Andrian U H. 2003. Selective imprinting of gut-homing T cells by Peyer’s patch dendritic cells. Nature, 424: 88–93.
33. 4+ T cells as key targets in mucosal transmission. PLoS Pathog, 7: e1001301.
34. 7. PLoS Pathog, 8: e1002686.
35. 7 is not a general property of most HIV-1 strains. J Virol, 88: 10767–10777.
36. 7. J Biol Chem, 287: 15749–15759.
37. Qin X F, An D S, Chen I S, Baltimore D. 2003. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA, 100: 183–188.
38. 7 in HIV transmission and pathogenesis. Barcelona, Spain, pp. 73.
39. P in lymphocyte adherence to fibronectin and VCAM-1 and in homotypic cell clustering. J Cell Biol, 117: 179–189.
40. Sagar M, Wu X, Lee S, Overbaugh J. 2006. Human immu nodeficiency virus type 1 V1–V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol, 80: 9586–9598.
41. Sattentau Q. 2008. HIV’s gut feeling. Nat Immunol, 9: 225–227.
42. Spurrier B, Sampson J, Gorny M K, Zolla-Pazner S, Kong X P. 2014. Functional Implications of the Binding Mode of a Human Conformation-dependent V2 Monoclonal Antibody against HIV. J Virol.
43. Temchura V, Tenbusch M. 2014. The two faces of vaccin e-induced immune response: protection or increased risk of HIV infection?! Virol Sin, 29: 7–9.
44. 7 subunit: identification of domains involved in adhesion to MAdCAM-1. J Immunol, 159: 1497–1505.
45. Tiscornia G, Singer O, Ikawa M, Verma I M. 2003. A gener al method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci USA, 100: 1844–1848.
46. Tjomsland V, Ellegard R, Kjolhede P, Wodlin N B, Hinkula J, Lifson J D, Larsson M. 2013. Blocking of integrins inhibits HIV-1 infection of human cervical mucosa immune cells with free and complement-opsonized virions. Eur J Immunol, 43: 2361–2372.
47. SF162P3N infection. Retrovirology, 11: 22.
48. 4+ T cell depletion and viral replication in SIV infection. Science, 280: 427–431.
49. 4+ T-cell loss in SIV infection. Mucosal Immunol, 2: 518–526.
50. Wawer M J, Gray R H, Sewankambo N K, Serwadda D, Li X, Laeyendecker O, Kiwanuka N, Kigozi G, Kiddugavu M, Lutalo T, Nalugoda F, Wabwire-Mangen F, Meehan M P, Quinn T C. 2005. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis, 191: 1403–1409.
51. Wurm F M. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol, 22: 1393–1398.
52. Wyatt R, Kwong P D, Desjardins E, Sweet R W, Robinson J, Hendrickson W A, Sodroski J G. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature, 393: 705–711.
53. 7, an integrin that mediates rolling adhesion. J Cell Biol, 196: 131–146.
54. 7 integrin function. J Cell Biochem, 83: 304–319.
55. 4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc Natl Acad Sci USA, 101: 5640–5645.